Invex Therapeutics Ltd (IXC.AX)
AUD 0.07
(-10.67%)
AUD 0.07
(-10.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 1.21 Million AUD | 164.06% |
| 2023 | 459.08 Thousand AUD | 151.9% |
| 2022 | 182.25 Thousand AUD | 0.0% |
| 2021 | - AUD | 0.0% |
| 2020 | - AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | - AUD | -100.0% |
| 2024 Q2 | - AUD | 0.0% |
| 2024 Q4 | 1.21 Million AUD | 0.0% |
| 2023 Q3 | 79.33 Thousand AUD | -45.84% |
| 2023 FY | 459.08 Thousand AUD | 151.9% |
| 2023 Q4 | 158.67 Thousand AUD | 100.0% |
| 2023 Q2 | 146.49 Thousand AUD | 197.53% |
| 2023 Q1 | -150.2 Thousand AUD | -462.59% |
| 2022 Q2 | -140.82 Thousand AUD | -100.0% |
| 2022 Q1 | -70.41 Thousand AUD | 0.0% |
| 2022 FY | 182.25 Thousand AUD | 0.0% |
| 2022 Q4 | 41.42 Thousand AUD | 100.0% |
| 2022 Q3 | 20.71 Thousand AUD | 114.71% |
| 2021 FY | - AUD | 0.0% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2021 Q3 | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 FY | - AUD | 0.0% |
| 2020 Q4 | - AUD | 0.0% |
| 2020 Q3 | - AUD | 0.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2019 Q3 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 97.62% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 261.869% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -11687.787% |
| Biome Australia Limited | 7.66 Million AUD | 84.194% |
| Patrys Limited | 1.39 Million AUD | 13.048% |
| Orthocell Limited | 3.68 Million AUD | 67.133% |
| Imugene Limited | -5.83 Million AUD | 120.758% |
| Noxopharm Limited | -534.81 Thousand AUD | 326.67% |
| PYC Therapeutics Limited | 22.05 Million AUD | 94.505% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 83.736% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 67.345% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 207.93% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 47.649% |
| CSL Limited | 15.28 Billion AUD | 99.992% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 4766.292% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 502.143% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 98.448% |
| Starpharma Holdings Limited | 7.65 Million AUD | 84.168% |
| Nanollose Limited | -348.95 Thousand AUD | 447.399% |
| Memphasys Limited | 1606.00 AUD | -75382.939% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 1427.234% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 69.775% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 118.503% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 3.142% |
| Race Oncology Limited | 1.38 Million AUD | 12.782% |
| Nyrada Inc. | -5164.07 AUD | 23574.817% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.607% |
| Dimerix Limited | 583.47 Thousand AUD | -107.764% |
| PharmAust Limited | -1641.00 AUD | 73973.004% |
| Immutep Limited | 1.44 Million AUD | 16.043% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 89.465% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 68.14% |
| BTC Health Limited | 16.36 Thousand AUD | -7309.878% |
| Acrux Limited | -1.28 Million AUD | 194.412% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 99.409% |
| Biotron Limited | -40.49 Thousand AUD | 3093.373% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -705.427% |
| AdAlta Limited | 1.5 Million AUD | 19.607% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 105.689% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -163.307% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -2033.803% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 430.524% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 2868.024% |
| Actinogen Medical Limited | 9.93 Million AUD | 87.794% |
| Immuron Limited | 3.33 Million AUD | 63.67% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 53.338% |